Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Oxis International, ... Eaton , the election of Anthony J. Cataldo ... President. Effective November 19, 2014, Ken Eaton ... of the Board of Directors of Oxis International, Inc. to ... has been named Chief Executive Officer of Oxis International, ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of $50,000,000 ... effective shelf registration statement. The offering will consist of ... price of $1.005 per share.  Lexicon has also granted ... 7,462,687 additional shares of common stock.  All of the ...
(Date:11/18/2014)... Mass. , Nov. 18, 2014  NxStage ... ), a leading manufacturer of innovative dialysis ... new  Streamline® Express dialyzer for the in-center, ... tubing set, which is designed to reduce the ... to reduce the number of touch point contamination ...
Breaking Medicine Technology:OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
... NEW YORK, Dec. 8, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p090656/Global-Gamma/Scintillation-Cameras-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Camera This ... Cameras in US$ Thousand by the following ...
... YORK, Dec. 8, 2011 Reportlinker.com announces ... available in its catalogue: , Global ... http://www.reportlinker.com/p090661/Global-Pulse-Oximeters-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Respirato This report ... in Thousands of US$ by the following ...
Cached Medicine Technology:Global Gamma/Scintillation Cameras Industry 2Global Gamma/Scintillation Cameras Industry 3Global Gamma/Scintillation Cameras Industry 4Global Gamma/Scintillation Cameras Industry 5Global Gamma/Scintillation Cameras Industry 6Global Gamma/Scintillation Cameras Industry 7Global Gamma/Scintillation Cameras Industry 8Global Gamma/Scintillation Cameras Industry 9Global Gamma/Scintillation Cameras Industry 10Global Gamma/Scintillation Cameras Industry 11Global Gamma/Scintillation Cameras Industry 12Global Gamma/Scintillation Cameras Industry 13Global Gamma/Scintillation Cameras Industry 14Global Gamma/Scintillation Cameras Industry 15Global Gamma/Scintillation Cameras Industry 16Global Gamma/Scintillation Cameras Industry 17Global Gamma/Scintillation Cameras Industry 18Global Gamma/Scintillation Cameras Industry 19Global Pulse Oximeters Industry 2Global Pulse Oximeters Industry 3Global Pulse Oximeters Industry 4Global Pulse Oximeters Industry 5Global Pulse Oximeters Industry 6Global Pulse Oximeters Industry 7Global Pulse Oximeters Industry 8Global Pulse Oximeters Industry 9Global Pulse Oximeters Industry 10Global Pulse Oximeters Industry 11Global Pulse Oximeters Industry 12Global Pulse Oximeters Industry 13Global Pulse Oximeters Industry 14Global Pulse Oximeters Industry 15Global Pulse Oximeters Industry 16Global Pulse Oximeters Industry 17Global Pulse Oximeters Industry 18
(Date:11/22/2014)... 22, 2014 Nocturia is defined ... complaint that the individual has to wake at ... report “Nocturia – Pipeline Review, H2 2014” provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:11/22/2014)... (HealthDay News) -- The wide variety and complexity of ... for people with food allergies, an expert warns. ... types of food allergies that it can be really ... Guha Krishnaswamy, director of allergy and clinical immunology at ... news release. "If you know you have food ...
(Date:11/22/2014)... 22, 2014 Hastings and Hastings, a ... experience announces providing clients with the option of leaving ... clients a flexible, intuitive and easy to navigate website ... access to Google + allows clients to research the ... a more informed decision when retaining an attorney. Those ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... President and Chief Executive Officer , , ... Bulletin Board: PSTX) today announced that David Bruce has ... Officer and will also join its Board of Directors. ... remain involved with the company as a consultant.David brings ...
... to the growing consumer demand for weight loss surgery, the number ... to infiltrate the industry. Selecting a board-certified surgeon who is a ... safe, permanent weight loss options. , ... (Vocus) January ...
... have now reported that exposure to cellphones, especially after 9 p.m., ... be that cell phone radiation, as well as those from other ... of damaging free radicals in the cerebrospinal fluid (CSF) and simultaneously ... ...
... drive toward containing health care costs could have the ... perhaps even increasing costs, two Beth Israel Deaconess Medical ... of Medicine "Perspective." , Citing studies in behavioral ... MD, express the fear that assigning a monetary value ...
... 7 Ambulatory Services of America,Inc. announced that ... in,ROSA of Georgia, LLC, a joint venture between ... American Oncology Associates, LLC.,Following the purchase, Radiation Oncology ... ROSA of Georgia. , ...
... BioMedical Enterprises, Inc. (BME), a cutting edge medical ... metal implants, announced today that it has appointed Kenneth ... W. Casey Fox, PhD, P.E., BME,s Founder, will ... efforts on building BME,s innovative product offerings. BME specializes ...
Cached Medicine News:Health News:Patient Safety Technologies Announces Expansion of Senior Management Team 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 3Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3Health News:Cost containment focus could have consequences for health care delivery 2Health News:Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC 2Health News:BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer 2
... The SoftTech Health Lab QMS (Quality ... quality management system built specifically for ... designed to help you meet quality ... so your staff has more time ...
... thawing systems are automated, easy to operate ... the outside environment by flexible snap-seal pockets ... or viral contamination of the water. Offered ... systems can also accommodate bags of various ...
Uses a rocking action to stir the plasma. Frozen plasma floats back and forth inside the plasma bag to speed thawing....
Conventional Digitally-Controlled Water Baths...
Medicine Products: